Ongoing CRIS projects: general psychiatry
ED RESTRAINT
In this research we will explore what information gets recorded on the use of restrictive practices in the treatment of children and young people who have an eating disorder. Restrictive practices include actions like stopping someone from moving by holding them down, feeding someone via a tube that passes into the stomach through the nose (nasogastric tubes), and limits on personal freedom. For this research we will use information from NHS health records through the Clinical Record Interactive Search (CRIS) system. We will use the records from people who have had treatment for an eating disorder. The information that we use will not have names or details that could identify people. We will explore the records to find out what types of restrictive practices are documented, how they are documented and where they are documented. We will describe patterns and frequencies of types of restrictive practices according to different settings and demographics (e.g. age and previous diagnoses). We will use this information to learn about children and young people’s time in hospital and times where restrictive practices were used. Using these health records means we can learn from the care of lots of people without asking people to take part in the study directly. What we learn will help us better understand restrictive practices, this will contribute to a bigger project to make eating disorder care safer.
PATHWAYS EI
Many children and young people wait a long time for help from mental health services. Much of what happens to them is written in notes by the staff who care for them, not recorded in tick boxes. This makes it hard for services to see why young people were referred, how long they waited, what help they were offered, what help they received and who is being missed.
In this study we will use pseudonymised records from Oxford Health’s mental health services for children and young people. We will build a computer tool that reads the notes inside a secure system and turns them into simple counts, such as the time from referral to first appointment or the type of support offered. The tool will first look at young people with anxiety or low mood. Every result will be checked against the original notes, and we will report where information is missing rather than guess it.
A group of young people and families with lived experience will help us decide what to look for, how to describe it and what is acceptable to show. We will only report results about groups, never about individuals. We will share the findings with the services, with people who plan services and in research journals, and make the tool free for other services to use.
CHRONOSIG P1
Aims: This research will build clinical-decision tools to support clinicians in making decisions and triaging referrals in NHS clinical practice. The tools will identify and improve access to care for people who have traditionally been excluded from, underrepresented, or poorly served by mental health services in the UK, ensuring they receive equitable care.
Background: People needing treatment for mental health problems are often first seen by their general practitioners, in hospital Emergency Departments or even in educational settings and staff then refer them to mental health services. This network of referral routes converges on community mental health teams who make decisions about suitability for treatment, how urgently to see people and which specialist teams need to be involved. In routine care, all referrals are assessed or ‘triaged’ by a multi-disciplinary team and often require the person is clinically reviewed over multiple contacts to eventually decide on treatment pathways. In 2019 this referral process cost the NHS £326 million. Electronic health records contain data from clinical encounters between patients and professionals, over multiple visits and this creates a longitudinal ‘fingerprint’ of the patient’s mental health over time. These clinical records are a rich source of information, which is particularly pertinent to mental health because mental illness is largely expressed as language and behaviour and the primary tool for the clinician is the interview, recorded as clinical notes and correspondence. However, this information is voluminous and time consuming to process (even by expert clinicians) when triaging referrals. Recent advances in artificial intelligence and natural language processing will help unlock this information to make triage more efficient and access to care more robust.
Work plan: Using a decade’s worth of observational data from the largest collection of the secondary care mental health electronic health records in the UK alongside state-of-the art neural network algorithms for natural language processing, we will develop, train and validate models capable of characterising a patient’s trajectory directly from clinical notes. The model’s effectiveness, safety and efficiency will be evaluated in simulated multidisciplinary triage teams at four NHS Foundation Trusts for pre-clinical use.
Patient and public involvement: Through the Patient and Public Involvement group of the Oxford Health Biomedical Research Centre, patients, carers and clinicians will be involved throughout with regular meetings for co-producing the project scope, milestones and evaluating the clinical efficacy, safety and ethical boundaries of the clinical decision support tools. Deliverables: An intelligent operational automation tool, based on a longitudinal patients’ trajectory derived from historical observations, will help streamline the process of being referred to an NHS mental health team. It will also help identify people with the highest care needs and suitable for services and clinical trials.
Prescribing gabapentinoids
Gabapentin and pregabalin (together called the ‘gabapentinoids’) are drugs prescribed and taken by many people in the US and UK. Common reasons for taking these medications are to decrease anxiety, reduce epileptic fits/seizures and alleviate pain related to nerve damage. However, often these medications are prescribed for disorders in which they have not been licensed (i.e. passed formal medical regulatory approval and recommendation for use). For instance, in patients with bipolar disorder the gabapentinoids are given to help with mood improvement, but there is no good evidence to suggest that they really work. Importantly, studies have shown that these medications can have troublesome side effects, some of which are potentially dangerous. These include dizziness, drowsiness, difficulty concentrating, blurred vision, movement disturbances and accidental injury. Furthermore, there is an increased risk of death by overdose when taken with drugs such as opioids (which include commonly prescribed painkillers such as codeine and illegal drugs such as ‘heroin’). For these reasons, the gabapentinoids were labelled as ‘controlled’ substances in the UK in 2019. This means that they are subject to more stringent measures and monitoring in clinical practice.
By conducting this study, we would like to examine the overall trends in the usage of pregabalin and gabapentin in real-world NHS practice, using the Oxford Health CRIS platform. This platform allows researchers to conduct patient-level research without being able to identify patients (hence maintaining individual anonymity). We also hope to demonstrate whether the 2019 regulatory change made an impact on the use of these medications.
Chronosig P3
Aims: We will build clinical-decision tools to support clinicians in making decisions and triaging referrals in NHS clinical practice. The tools will identify and improve access to care for people who have traditionally been excluded from, underrepresented, or poorly served by mental health services in the UK, ensuring they receive equitable care.
Background: People needing treatment for mental health problems are often first seen by their general practitioners, in hospital Emergency Departments or even in educational settings and staff then refer them to mental health services. This network of referral routes converges on community mental health teams who make decisions about suitability for treatment, how urgently to see people and which specialist teams need to be involved. In routine care, all referrals are assessed or ‘triaged’ by a multi-disciplinary team and often require the person is clinically reviewed over multiple contacts to eventually decide on treatment pathways. In 2019 this referral process cost the NHS £326 million. Electronic health records contain data from clinical encounters between patients and professionals, over multiple visits and this creates a longitudinal ‘fingerprint’ of the patient’s mental health over time. These clinical records are a rich source of information, which is particularly pertinent to mental health because mental illness is largely expressed as language and behaviour and the primary tool for the clinician is the interview, recorded as clinical notes and correspondence. However, this information is voluminous and time consuming to process (even by expert clinicians) when triaging referrals. Recent advances in artificial intelligence and natural language processing will help unlock this information to make triage more efficient and access to care more robust.
Work plan: Using a decade’s worth of observational data from the largest collection of the secondary care mental health electronic health records in the UK alongside state-of-the art neural network algorithms for natural language processing, we will develop, train and validate models capable of characterising a patient’s trajectory directly from clinical notes. The model’s effectiveness, safety and efficiency will be evaluated in simulated multidisciplinary triage teams at four NHS Foundation Trusts for pre-clinical use.
Patient and public involvement: Through the Patient and Public Involvement group of the Oxford Health Biomedical Research Centre, patients, carers and clinicians will be involved throughout with regular meetings for co-producing the project scope, milestones and evaluating the clinical efficacy, safety and ethical boundaries of the clinical decision support tools.
Deliverables: An intelligent operational automation tool using medical information extracted from historical clinical records, will help streamline the process of being referred to an NHS mental health team. It will also help identify people with the highest care needs and suitable for services and clinical trials.
Service Economic Evaluation
The NHS is constantly re-organising in order to meet the different care needs of individuals. However, to maximise efficiencies, prioritise programmes and improve services, a data review is required. This project will extract and examine how much the data collected by NHS Trusts as part of usual care can be used to inform and improve NHS services. This would include an explorative evaluation of Early Intervention in Psychosis services to understand what areas of data collection need to improve and what valuable research is possible at the moment.
RECOLLECT
This project is part of the larger RECOLLECT Programme Grant for Applied Research awarded by the NIHR funding collaborative, multidisciplinary programmes of applied research to solve health and social care challenges. (NIHR200605) which aims to develop the evidence base for Recovery Colleges in England and understand how they can provide the most benefit to people who use mental health services. We will compare Recovery College students with mental health service users who do not attend the Recovery College in order to explore the effectiveness and cost-effectiveness of Recovery Colleges.
Child Refugee
Refugee and asylum-seeking children and young people often struggle with mental health problems. Many studies have shown an urgent need for treatments that address mental health problems in this population. However, refugee and asylum-seeking children and young people face significant barriers when trying to access the support they need. These barriers can include language barriers, cultural differences in conceptualisation of mental health, limited resources, and difficulties navigating the healthcare system in a new country. Even when they do manage to access treatment, there is still a lack of understanding about the specific mental health symptoms and problems they face as well as the treatment that is offered and received. This knowledge gap makes it challenging for healthcare professionals to provide targeted and effective support.
ClinicalInstabilityPredictorHonos
The clinical global impressions scale (CGI) is a very brief assessment of a patient’s mental health. It asks one question to the clinician asking how mentally unwell a patient is at the visit, rated from 0-7 (with 0 being not at all mentally unwell and 7 being among the most unwell patients). A previous study published in Lancet Psychiatry last year (https://doi.org/10.1016/S2215-0366(23)00066-4) showed that patients whose CGI scores fluctuated more were more likely to be admitted to hospital than those who were more stable.
If this concept holds true, it should be applicable to other measures, like the Health of the Nation Outcome Scales (HoNOS), which is used routinely in the Trust. HoNOS has clinicians rating a patient from 0-4 on 12 domains measuring behaviour, impairment, symptoms and social functioning. We want to test whether instability in HoNOS scores can predict how likely a patient is of being admitted to hospital.
Transition to Schizophrenia
This project aims to predict patients’ likelihood of developing schizophrenia after experiencing substance-induced psychosis. I will extract electronic health record data to study the demographic, social, and clinical factors associated with a new diagnosis of schizophrenia or other permanent psychoses following substance-induced psychosis.
I will use these findings to develop and validate a web-based calculator that calculates the likelihood a person with substance-induced psychosis develops permanent psychoses at a specific time in the future. Two separate datasets will be used for development (South London and Maudsley NHS Foundation Trust) and validation (Oxford Health NHS Foundation Trust) respectively.
Nasogastric PTSD
Compulsory nasogastric feeding usually involves the physical restraint of patients by several staff members to insert a narrow bored tube into the nose, through a hole in the back of the nose and into the stomach. After checking that the tube is in the stomach, a nutritionally dense liquid feed can be administered. This can be life saving when a patient with an eating disorder is a very low weight and unable to improve their nutritional status by eating or drinking.
The procedure can be highly distressing and sedation is rarely offered. Psychological distress and even PTSD symptoms have been reported. Concerns have also been raised about retraumatising people who have suffered assault (who unfortunately make up a significant proportion of patients with eating disorders). Sadly, the fear of nasogastric feeding has led to avoidance of care that could have treated the eating disorder.
No studies, to our knowledge, have systematically investigated how many people develop psychological distress, following compulsory nasogastric feeding. A large scale study is needed to answer this question and to establish what factors predict the development of these symptoms and whether the use of sedation prevents it.
The proposed study is to use the CRIS facility to anonymously and electronically scan case notes, for reports of psychological distress, together with the severity, longevity and impact. A further analysis will test a range of factors that might make a person more likely to develop such distress and if possible, whether sedation reduces this.
Clozapine trials
Clozapine is a highly effective medicine for people with schizophrenia who do not improve with standard treatments. It is the only recommended drug for treatment-resistant schizophrenia and can greatly reduce hospital admissions, suicide risk, violence, and substance misuse. However, clozapine can cause serious side effects, including problems with blood cells, meaning patients need regular blood tests. Because of these risks, and a lack of research in younger people, clozapine is rarely prescribed to children and young adults, even when it may be the most appropriate treatment.
Studying clozapine in young people is challenging. Traditional clinical trials are difficult because many patients are very unwell, may not be able to give informed consent, and are often unwilling to be randomly assigned to treatments. To address this, the CLEAR-EHR study uses a different approach called a “target trial”, which analyses existing, anonymised electronic health records.
The study will compare clozapine with standard antipsychotic treatment in young people aged 12–24 with treatment-resistant schizophrenia. By combining large-scale real-world data with detailed clinical studies, this research aims to provide stronger evidence about whether clozapine is effective and safe for young people, helping to improve treatment decisions and future guidelines.
Page last reviewed: 16 October, 2026
